GoodRx Holdings, Inc. (GDRX)

GoodRx Holdings Financials Overview

Financials in millions USD. Fiscal year is January - December.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue Revenue Growth	785.23	796.85	792.32	750.27	766.55	745.42
Revenue Growth	-1.83%	0.57%	5.61%	-2.13%	2.83%	35.36%
Gross Profit Gross Profit Growth	713.19	739.26	744.11	687.84	701.48	698.71
Operating Income Operating Income Growth	89.24	106.2	86.2	49.5	19.8	13.41
Net Income Net Income Growth	16.25	30.44	16.39	-8.87	-32.83	-25.25
Earnings Per Share EPS Growth	0.05	0.09	0.04	-0.02	-0.08	-0.06
EPS Growth	-46.78%	113.56%	-	-	-	-

Revenue by Segment

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Prescription Transactions Prescription Transactions Growth	472.1	544	577.55	550.74	550.54	593.36
Subscription Subscription Growth	95.21	83.79	86.54	94.41	96.17	59.93
Pharma Direct Pharma Direct Growth	201.61	151.38	107.24	85.07	99.43	73.35
Other Service Other Service Growth	16.31	17.69	21	20.05	20.43	18.79
Revenue (Total) Revenue (Total) Growth	785.23	796.85	792.32	750.27	766.55	745.42

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Investments Cash & Investments Growth	296.11	261.82	448.35	672.3	757.17	941.11
Total Debt Total Debt Growth	538.95	542.81	543.39	711.07	717.02	702.33
Net Cash (Debt) Net Cash Growth	-242.84	-280.99	-95.04	-38.77	40.14	238.78
Net Cash Growth	-	-	-	-	-83.19%	-9.47%
Net Cash Per Share Net Cash Per Share Growth	-0.70	-0.79	-0.24	-0.09	0.10	0.58

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Operating Cash Flow Operating Cash Flow Growth	201.58	167.9	183.89	138.29	146.78	178.78
Capital Expenditures CapEx Growth	-4.49	-3.52	-1.24	-1.04	-3.97	-4.57
Free Cash Flow Free Cash Flow Growth	197.09	164.38	182.65	137.25	142.81	174.21
Free Cash Flow Growth	4.01%	-10.00%	33.08%	-3.90%	-18.02%	57.24%

Margins

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Gross Margin	90.83%	92.77%	93.92%	91.68%	91.51%	93.73%
Operating Margin	11.37%	13.33%	10.88%	6.60%	2.58%	1.80%
Pretax Margin	5.27%	7.10%	3.97%	-7.41%	-3.03%	-1.37%
Profit Margin	2.07%	3.82%	2.07%	-1.18%	-4.28%	-3.39%
FCF Margin	25.10%	20.63%	23.05%	18.29%	18.63%	23.37%

Valuation

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
PE Ratio	73.10	30.22	109.17	-	-	-
Forward PE	32.13	18.85	27.04	186.56	167.96	267.21
P/FCF Ratio	6.02	5.60	9.80	19.83	12.93	74.83
PS Ratio	1.51	1.15	2.26	3.63	2.41	17.49

Data Sources: S&P Global Market Intelligence and Fiscal.ai Last updated: Aug 5, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company. Revenue segment data is provided by Fiscal.ai.

Update frequency:

Quarterly

Last checked:

Aug 31, 2026

Data Sources Report a data error